Artificial intelligence delivers meaningful value in drug development only when it is grounded in real-world constraints and tightly integrated into expert-led workflows, rather than treated as a standalone, model-first solution.
Christine Allen, PhD
Advertisement
Christine Allen, PhD, is co-founder and CEO of Intrepid Labs.
Articles by Christine Allen, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Rare Disease Framework Initiative: What It Means for Drug and Biologic Development
2
FDA Accepts BLA for Formycon and Zydus’ FYB206, the First Publicly Announced Keytruda Biosimilar Under Review
3
Gilead Taps Vir Biotechnology's PRO-XTEN Tech for Solid Tumors
4
FDA’s ARC Program Highlights Opportunities and Limits of Bayesian Methods in Rare Disease Trials
5